Updates Center

• 
  COMPANY ANNOUNCEMENT

  AtaGenix Laboratories Co., Ltd. issues a formal statement addressing the unauthorized use of its name by Wuhan Biolab-reagent, which forged documents and official seals, constituting illegal activity and unfair competition. The company clarifies that no business agreements exist with Wuhan Biolab-reagent, condemns their actions, and reserves the right to pursue legal action under Chinese intellectual property and criminal laws. AtaGenix advises partners to verify document authenticity to avoid legal and financial risks, reaffirming its commitment to honest operation and industry fairness.
• 
  International Life Sciences Leaders Visit AtaGenix: Advancing Antibody R&D with Velocity and Rigor

  On October 14, 2025, AtaGenix in Wuhan, China, welcomed global life sciences representatives to explore its 6-month antibody R&D platform, marking a biotech collaboration milestone.
• 
  AtaGenix October 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  In October 2025, AtaGenix delivered critical antibody solutions for seven groundbreaking studies published in Cell (IF 42.5), Nature Plants (IF 13.6), and other leading journals. Research spanned insect endosymbiont tubenets, Bacteroidota T6SS co-secretion, Brassica pancentromere dynamics, lysosomal damage in Duchenne muscular dystrophy, and more. Custom anti-Lpp, CENH3, SiFBA4, and anti-R99me2a antibodies enabled immunogold labeling, ChIP-seq, protein quantification, and translational regulation studies—overcoming key experimental hurdles. Over 500 SCI papers have now cited AtaGenix’s one-stop protein and antibody development platform. The ongoing literature reward program continues to incentivize citations.
• 
  AtaGenix September 2025 Literature Collection: Advancing Life Sciences Through Cutting-Edge Research Support

  The AtaGenix September 2025 Literature Collection highlights the company’s pivotal role in supporting groundbreaking life science research. Featuring studies published in high-impact journals like Journal of Nanobiotechnology and Cell Reports, this collection showcases advancements in lipid nanoparticle-based mRNA vaccines, gastric cancer drug resistance mechanisms, LayV virus antigenicity, jujube centromere evolution, and tomato plant vigor regulation. AtaGenix’s technical services, including custom antibodies and hybridoma screening tools, were instrumental in these discoveries, reinforcing its commitment to driving innovation in life sciences.
• 
  VINS Visits AtaGenix Wuhan HQ for Biopharma Partnership

  On June 25, 2025, VINS Bioproducts visited AtaGenix’s Wuhan headquarters to expand collaboration on vaccine raw materials, antibody R&D, and CRO services—advancing public health and innovation.
• 
  AtaGenix Excels at Thailand LAB International 2025: Pioneering Antibody Discovery & Protein Expression

  AtaGenix Laboratories Co., Ltd. participated in Thailand LAB International 2025 in Bangkok from September 3-5, showcasing advanced antibody discovery and protein expression technologies at booth 2S21. Through technical exhibits, seminars, and business discussions, AtaGenix established global partnerships, reinforcing its leadership in the Asia-Pacific biotechnology market.
• 
  Meet AtaGenix at LAB International Thailand 2025 | Booth 2S21 | September Exhibition

  AtaGenix will participate in LAB International 2025, taking place in Thailand from September 3 to 5, 2025. Visit Booth 2S21 to explore our capabilities in antibody discovery, engineering, protein expression, and purification, as well as the abinScience portfolio of recombinant proteins and antibodies. Let’s connect and discuss potential collaborations.
• 
  BioTAG Visits AtaGenix Headquarters to Advance Antibody Drug Development and Precision Medicine

  On August 13, 2025, BioTAG from Israel visited AtaGenix’s Wuhan headquarters to discuss antibody drug development, protein engineering, and CRO services. The collaboration aims to advance precision medicine and biopharmaceutical innovation globally.
• 
  Antibody Discovery Paradigm Shift: Single B-Cell Cloning Challenges Phage Display Dominance

  On September 29, 2025, the antibody development field sees a pivotal shift as single B-cell cloning gains momentum, challenging the dominance of phage display. Known for its vast libraries, phage display is being rivaled by B-cell cloning’s ability to capture high-affinity, natural antibodies with low immunogenicity. AtaGenix leverages both platforms, offering services like antibody development, recombinant protein expression, and humanization to accelerate client projects, reducing discovery timelines by over 30%.
• 
  Analysis Forecasts First Commercial Bispecific ADC Launch by 2029 Amid Surging Clinical Pipeline

  A recent industry analysis forecasts the first commercial launch of a bispecific antibody–drug conjugate (BsADC) by 2029, marking a major milestone in multispecific biologics. With 100+ BsADC candidates in clinical development, including more than 60 from China, the field is expanding rapidly. Advances in linker–payload technologies, bispecific formats, and regulatory learning from earlier ADCs are accelerating progress. For developers, this trend highlights both opportunity and competition. AtaGenix supports BsADC innovation with expertise in bispecific design, conjugation strategies, and early-stage engineering—helping partners gain a competitive edge in next-generation oncology therapeutics.